Ginkgo: old ingredient, modern focus claims

Ginkgo has been on the memory-and-focus shelf for so long that it's easy to assume somebody settled the question years ago. It's a tree the US National Center for Complementary and Integrative Health calls a "living fossil", a leaf extract with a reputation for sharper thinking, and a very large pile of trials. What those trials show depends on who took it, which extract they took, and what else was in their medicine cabinet. Let's go through them in that order.

The headline version: in healthy adults, reviews of randomised trials find no reliable cognitive benefit. In older adults, two large trials found that a standardised extract did not prevent dementia or slow cognitive decline. In people who already have dementia, results are mixed, with some analyses of the standardised extract EGb 761 finding modest benefits and the most recent Cochrane review finding possible small to moderate benefits at six months, from low-certainty evidence. Ginkgo also has real interaction and bleeding cautions that which is why they get their own section further down.

Who the trials actually studied

• Group studied: Healthy adults, including under-60s; Typical finding: No convincing cognitive benefit in reviews and meta-analyses; What it means for "focus": Nothing here supports a boost in healthy people
• Group studied: Older adults without dementia (prevention trials); Typical finding: No effect on dementia incidence or on rate of cognitive decline; What it means for "focus": Not a protective strategy on current evidence
• Group studied: People with mild cognitive impairment; Typical finding: Cochrane 2026: probably little or no effect at six months; What it means for "focus": Not established
• Group studied: People with dementia; Typical finding: Mixed; some positive meta-analyses of one extract, possible small to moderate effects in the latest Cochrane review (low-certainty); What it means for "focus": A medical question, not a self-help one

What's in a ginkgo capsule?

"Ginkgo" on a label can mean quite different things.

A standardised extract. Most of the clinical research uses one specific preparation, EGb 761, a point the Cochrane reviewers make directly (Birks & Grimley Evans 2009). The European Medicines Agency (EMA) describes the extract behind its licensed-medicine monograph as a dry extract made from leaf with a 35 to 67:1 drug-to-extract ratio, extracted with 60% acetone and refined to 22 to 27% flavone glycosides and 5 to 7% terpene lactones, in line with the European Pharmacopoeia monograph for "Ginkgo dry extract, refined and quantified" (EMA assessment report).

Powdered leaf. The same EMA monograph has a separate "traditional use" section for powdered leaf, aimed at a different job: heaviness of legs and cold hands and feet linked to minor circulatory problems, at 250 to 360 mg per dose (EMA monograph). Dose and preparation are different from the extract, and so is the claimed purpose, so trial results for one can't be pasted onto the other.

Anything in between. A 2024 review that pooled adulteration reports for five popular herbs found ginkgo leaf had the highest rate: 56.7% of 533 samples were reported as adulterated or mislabelled, though the authors stress significant limits to the underlying data and note that licensed herbal medicines fared better than food supplements (Orhan et al. 2024). A separate analysis of 63 ginkgo products on the German market, based on package inserts, rated supplements as less reliable than licensed drugs on criteria such as active-ingredient targets (Trabert & Seifert 2024). Both are about the situation in the studied markets, not about any product you might be holding, but they explain why labels are worth reading.

The ginkgolic acid limit

Crude ginkgo extracts contain alkylphenols such as ginkgolic acids, which the EMA's assessment report says have potential contact-allergenic and toxic properties. To comply with the European Pharmacopoeia and to ensure safety, ginkgo leaf extracts must keep them at a maximum of 5 ppm, a value chosen because it matches the detection limit of routine methods (EMA assessment report). For a supplement, "ginkgolic acid below 5 ppm" on a label or specification sheet is therefore a meaningful quality marker, and a missing one is a fair question to ask.

Healthy adults: the focus question

This is the group most readers of a "focus" article belong to, and the answer is consistently flat.

• A 2007 systematic review of 15 randomised, placebo-controlled trials in healthy people under 60 (single-dose and longer studies) found no convincing evidence of a robust positive effect on any aspect of cognition (Canter & Ernst 2007).
• A 2012 meta-analysis pooled randomised trials in healthy individuals and found effect sizes close to zero for memory (13 trials, 1,132 participants), executive function and attention (Laws et al. 2012).
• In a six-week trial of 230 healthy adults over 60 taking 40 mg three times a day, ginkgo didn't improve memory, attention or language on neuropsychological tests, or on self-rated or companion-rated memory (Solomon et al. 2002).

Ginkgo is often explained through blood flow. The EMA's monograph does note human pharmacology data showing improved cerebral blood flow in specific brain areas in healthy men aged 60 to 70, along with reduced blood viscosity, but it also states that the exact mechanism is not known (EMA monograph). A plausible mechanism and a measured improvement in thinking are two separate findings, and only the second one speaks to the shelf claim. None of the trials covered here looked at gaming performance.

Older adults and dementia prevention: GEM and GuidAge

Two large, long trials tested the standardised extract at 120 mg twice a day:

• GEM (Ginkgo Evaluation of Memory). 3,069 older volunteers (the two papers describe them as aged 75 or over, and as 72 to 96), with normal cognition or mild cognitive impairment, followed for a median of 6.1 years. Dementia rates were 3.3 per 100 person-years on ginkgo and 2.9 on placebo; the hazard ratio of 1.12 (95% CI 0.94 to 1.33) was not statistically significant, and adverse-effect profiles were similar (DeKosky et al. 2008). A companion paper found no difference in the rate of cognitive decline in any domain (Snitz et al. 2009). The research grants listed were from US public health institutes, and Schwabe Pharmaceuticals donated the EGb 761 tablets and matching placebo, according to the paper's funding statement.
• GuidAge. 2,854 people aged 70 or over with memory complaints in French primary care, followed for five years. Probable Alzheimer's disease was diagnosed in 61 people on the extract and 73 on placebo (hazard ratio 0.84, 95% CI 0.60 to 1.18, not significant); the trial was funded by the company Ipsen (Vellas et al. 2012).

Neither trial says ginkgo is harmful, and neither shows that it protects. NCCIH summarises GEM the same way: no difference in the rates at which participants developed dementia.

When cognitive impairment already exists

This is where ginkgo's story gets more interesting, and also more contested.

• A 2009 Cochrane review of 36 trials (most small and short) concluded that evidence of a predictable, clinically significant benefit in dementia or cognitive impairment was "inconsistent and unreliable", while ginkgo appeared safe (Birks & Grimley Evans 2009).
• A 2014 meta-analysis of seven placebo-controlled trials of EGb 761 (120 or 240 mg a day for 22 to 26 weeks, 2,625 patients analysed) found significant benefits for cognition, daily living and global rating (Gauthier & Schlaefke 2014). One of its two authors is affiliated with the pharmaceutical company Dr Willmar Schwabe.
• A 2015 meta-analysis of nine trials (2,561 patients, 22 to 26 weeks) by authors affiliated with a hospital in China and a US university found benefits mainly at 240 mg a day, especially in patients with neuropsychiatric symptoms (Tan et al. 2015).
• The most recent Cochrane review (2026) included 82 studies with 10,613 participants and graded the certainty of the evidence. It concluded that in people with mild cognitive impairment ginkgo probably has little or no effect at six months, while in people with dementia there may be small to moderate benefits at six months. That dementia finding is low-certainty evidence, and results varied widely between studies (I² of 88 to 96% for the main outcomes). Adverse events were probably little different up to 12 months. For people with subjective memory complaints only, the reviewers were unsure it helps and noted it may be linked to more adverse events at three months (Wieland et al. 2026).

So the picture has improved a little for dementia since 2009, but it hasn't become a recommendation. A 2026 review of 77 clinical guideline documents from 28 countries found that mentions of ginkgo were 52 positive, 18 negative and 26 neutral, usually without naming a specific preparation (Pfuhlmann et al. 2026). Dementia is a diagnosis for doctors, and managing it belongs with them rather than with a supplement shelf.

Safety: the part worth reading twice

Ginkgo is a plant extract with real pharmacology, so the interaction story is the most practically useful part of this page.

Bleeding and blood-thinning medicines. NCCIH says ginkgo may increase the risk of bleeding in people taking anticoagulant drugs such as warfarin. The EMA monograph says anticoagulants (phenprocoumon and warfarin) or antiplatelet drugs (clopidogrel, acetylsalicylic acid and other NSAIDs) may have their effect influenced, notes that available studies with warfarin do not indicate an interaction but advises adequate monitoring when starting, changing or stopping ginkgo, and advises stopping ginkgo as a precaution three to four days before surgery. The Dutch Medicines Evaluation Board (CBG) likewise says ginkgo herbal products can affect blood clotting and, taken with blood thinners, may lengthen clotting time (CBG).

There's a real nuance. A meta-analysis of 18 randomised trials (1,985 adults) found no evidence of higher bleeding risk from standardised ginkgo extract in laboratory haemostasis measures, such as platelet aggregation and clotting times (Kellermann & Kloft 2011), and in GuidAge other haemorrhagic or cardiovascular events didn't differ between groups. Those results are reassuring for lab values and trial participants, but regulators still advise caution, and the EMA lists bleeding of individual organs (eye, nose, brain and gut) among reported effects, with the frequency unknown. Anyone taking an anticoagulant or antiplatelet should ask a pharmacist or doctor before adding ginkgo.

Epilepsy and anticonvulsants. The EMA monograph says that in people with epilepsy, further seizures promoted by ginkgo cannot be excluded. Its assessment report discusses case reports, including two patients on sodium valproate who developed seizures within two weeks of taking ginkgo products, both of whom were also taking other medications (EMA assessment report). Case reports can't prove cause, which is why the wording is cautious. For anyone on epilepsy medication, it's a question for the prescriber.

Other medicines named by regulators. The EMA monograph advises against combining ginkgo with efavirenz, advises caution with dabigatran, and reports that one interaction study found nifedipine peak levels increased in some people. The CBG also says ginkgo can reduce the effect of digoxin.

Side effects. The EMA lists headache as very common and dizziness as common among people taking the licensed extract, along with diarrhoea, abdominal pain, nausea and vomiting, and allergic reactions. NCCIH says that for most adults, ginkgo leaf extracts are likely to be safe in moderate amounts, with dizziness, stomach upset and headache the common side effects. NCCIH also warns that fresh seeds are toxic, and roasted seeds can cause serious effects too.

Pregnancy, breastfeeding and under-18s. The EMA's licensed-medicine section contraindicates use in pregnancy and advises against it during lactation; the traditional-use section says use in pregnancy and lactation, and under 18, is not recommended. NCCIH says ginkgo may be unsafe during pregnancy.

If you take prescription medication, our guide to supplements, herbs and medication explains how to check combinations.

What EU and Dutch regulators say

Dated 8 October 2026. Rules change, so check current wording.

• EU medicines. The EMA's HMPC adopted its ginkgo leaf monograph on 28 January 2015, with a "well-established use" part for the standardised extract in age-associated cognitive impairment and mild dementia (120 to 240 mg per dose, 240 mg a day, treatment for at least 8 weeks, with review if no improvement after 3 months) and a "traditional use" part for the powdered leaf described above. The EMA site shows no revised version (read 8 October 2026).
• Netherlands. The CBG's ginkgo page (dated 5 March 2024) says no herbal medicines containing ginkgo are on the Dutch market, though they're available in other European countries, and that ginkgo supplements are on sale in the Netherlands but their health effects have not been officially demonstrated. The Dutch herbal-preparations decree (Warenwetbesluit Kruidenpreparaten) has an annex listing plants and fungi that herbal preparations must not contain (Article 4(2); it names kava and yohimbe, for example). Ginkgo is not named there, but that is not an approval: other rules, including EU novel-food law, are separate (wetten.overheid.nl, version in force from 1 July 2022 as shown on 8 October 2026). A January 2026 draft amendment to the decree exists, and its text was not opened, so don't treat the annex as final.
• Novel food. We couldn't confirm the EU novel-food status of ginkgo, so we make no statement about it. Check the Commission's Novel Food Status Catalogue before buying.

A ginkgo label, line by line

An invented label, for illustration only:

Ginkgo biloba leaf dry extract 50:1, standardised to 24% flavone glycosides and 6% terpene lactones, ginkgolic acids below 5 ppm. 120 mg per capsule.

• Extract ratio: 50:1 falls within the 35 to 67:1 range that the EMA describes, which suggests a concentrated extract rather than ground leaf.
• Markers: 24% and 6% sit inside the 22 to 27% and 5 to 7% ranges. A label that gives no markers can't be compared with the studied extract.
• Ginkgolic acid: "below 5 ppm" matches the pharmacopoeia limit. If a product doesn't state it, that's a reason to ask the manufacturer.
• Amount against the research: the large prevention trials used 120 mg twice a day (240 mg a day) of EGb 761, which is also the daily dose in the EMA's well-established-use section. That describes what was studied. It doesn't mean another extract at the same milligrams behaves the same way, and it isn't advice.
• Name: EGb 761 is a specific extract. "Ginkgo biloba extract" on a pack is not automatically EGb 761, and results for one can't be assumed for the other.

For the general method, our guide to reading supplement labels goes through it step by step.

Ginkgo for focus: what the trials add up to

Ginkgo is a well-studied, genuinely interesting leaf extract. Its best-known promise, better focus in healthy people, hasn't shown up in the trials reviewed above. The larger evidence base sits in older adults and dementia, where results are mixed and the questions belong with a doctor. What stands out practically is the safety side: bleeding-related cautions, epilepsy, some specific medicines and pregnancy. If those apply to you, ginkgo is a conversation for a pharmacist or doctor before it's a purchase.

Where to read next

Ginkgo is one name in a crowded focus aisle. For the wider shelf:

• Nootropics: what belongs in the category?, for where the word came from, what healthy-adult research shows and the Dutch rules.
• Bacopa: where does the memory interest come from?, for what the memory trials tested and where reviews disagree.
• Rhodiola: what the research does and doesn't show, for what named extracts show for fatigue, stress and focus and how to read the label.
• Lion's mane: the mushroom behind the focus claims, for why fruiting body, mycelium and extract labels matter.

Written by Smart Supplements with AI assistance from the sources linked in the text. It has not been reviewed by a clinician.

Last updated: 12 October 2026

This article is for informational purposes only and is not intended as medical advice. Always consult a healthcare professional before starting any new supplement, especially if you take prescription medication.